These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 33333862)

  • 1. Current Status on Therapeutic Molecules Targeting Siglec Receptors.
    Lenza MP; Atxabal U; Oyenarte I; Jiménez-Barbero J; Ereño-Orbea J
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in understanding and exploiting Siglec-glycan interactions.
    Jame-Chenarboo Z; Gray TE; Macauley MS
    Curr Opin Chem Biol; 2024 Jun; 80():102454. PubMed ID: 38631213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
    Linnartz-Gerlach B; Mathews M; Neumann H
    Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural advances of Siglecs: insight into synthetic glycan ligands for immunomodulation.
    Movsisyan LD; Macauley MS
    Org Biomol Chem; 2020 Aug; 18(30):5784-5797. PubMed ID: 32756649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tools to study and target the Siglec-sialic acid axis in cancer.
    Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
    FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of Recombinant Siglecs and Identification of Their Ligands.
    Chang LY; Low PY; Sridharan D; Gerlovin K; Angata T
    Methods Mol Biol; 2020; 2132():85-98. PubMed ID: 32306317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siglecs as targets for therapy in immune-cell-mediated disease.
    O'Reilly MK; Paulson JC
    Trends Pharmacol Sci; 2009 May; 30(5):240-8. PubMed ID: 19359050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands.
    Rodrigues E; Jung J; Park H; Loo C; Soukhtehzari S; Kitova EN; Mozaneh F; Daskhan G; Schmidt EN; Aghanya V; Sarkar S; Streith L; St Laurent CD; Nguyen L; Julien JP; West LJ; Williams KC; Klassen JS; Macauley MS
    Nat Commun; 2020 Oct; 11(1):5091. PubMed ID: 33037195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siglecs as modulators of macrophage phenotype and function.
    Kukan EN; Fabiano GL; Cobb BA
    Semin Immunol; 2024 May; 73():101887. PubMed ID: 39357273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.
    Angata T; Nycholat CM; Macauley MS
    Trends Pharmacol Sci; 2015 Oct; 36(10):645-660. PubMed ID: 26435210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
    Gianchecchi E; Arena A; Fierabracci A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
    Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
    Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Siglecs on autoimmune diseases.
    Brzezicka KA; Paulson JC
    Mol Aspects Med; 2023 Apr; 90():101140. PubMed ID: 36055802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the binding specificities of human Siglecs by cell-based glycan arrays.
    Büll C; Nason R; Sun L; Van Coillie J; Madriz Sørensen D; Moons SJ; Yang Z; Arbitman S; Fernandes SM; Furukawa S; McBride R; Nycholat CM; Adema GJ; Paulson JC; Schnaar RL; Boltje TJ; Clausen H; Narimatsu Y
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33893239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siglec Ligands.
    Gonzalez-Gil A; Schnaar RL
    Cells; 2021 May; 10(5):. PubMed ID: 34065256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
    Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
    Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting sialylation to treat central nervous system diseases.
    Lünemann JD; von Gunten S; Neumann H
    Trends Pharmacol Sci; 2021 Dec; 42(12):998-1008. PubMed ID: 34607695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties.
    Yu H; Gonzalez-Gil A; Wei Y; Fernandes SM; Porell RN; Vajn K; Paulson JC; Nycholat CM; Schnaar RL
    Glycobiology; 2017 Jul; 27(7):657-668. PubMed ID: 28369504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Siglec and anti-Siglec therapies.
    Murugesan G; Weigle B; Crocker PR
    Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.